Prophylactic and therapeutic monoclonal antibodies

• US 20020009447A1
• Filed: 02/09/2001
• Published: 01/24/2002
• Est. Priority Date: 02/11/2000
• Status: Active Grant

• Current Assignee: United States Army Medical Research and Materiel Command, United States Army (U.S. Department Of Defense)
• Original Assignee: United States Army Medical Research and Materiel Command
• Inventors: Hooper, Jay W., Schmaljohn, Connie S., Schmaljohn, Alan L.
• Granted Patent: US 6,451,309 B2
• Time in Patent Office: Days
• US Class Current: 424/147.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07K 16/081 from DNA viruses

Abstract

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Claims

1. A composition comprising one or more monoclonal antibody directed against a vaccinia virus antigen.

2. The composition of claim 1 wherein said vaccinia virus antigen is L1R.

3. The composition of claim 1 wherein said vaccinia virus antigen is A33R.

4. The composition of claim 2 wherein said composition further comprises one or more monoclonal antibody directed against vaccinia A33R.

5. The composition of claim 4 wherein said composition further comprises one or more monoclonal antibody directed against an antigen chosen from the group consisting essentially of:

vaccinia H3L, D8L, B5R, A27L and A17L.

6. The composition of claim 4 wherein said composition inhibits vaccinia virus infection in a subject in vivo.

7. The composition of claim 6 wherein said subject is avian or mammalian.

8. The composition of claim 4 wherein said composition ameliorates symptoms of vaccinia virus infection when said composition is administered to a subject after infection with vaccinia virus.

9. The composition of claim 8 wherein said subject is avian or mammalian.

10. The composition of claim 2 wherein said monoclonal antibody immunoprecipitates L1R in vitro.

11. The composition of claim 3 wherein said monoclonal antibody immunoprecipitates A33R in vitro.

12. A therapeutic composition for ameliorating symptoms of vaccinia virus infection comprising the composition of claim 4, and a pharmaceutically acceptable excipient.

13. A passive vaccine against vaccinia virus infection comprising the composition of claim 4.

15. A method of treating vaccinia virus infection comprising administering to a patient in need of said treatment an effective amount of a composition according to claim 4.

16. The composition according to claim 1 wherein said vaccinia virus antigen is chosen from the vaccinia strain Connaught, IHD-J, Brighton, WR, Lister, Copenhagen, Ankara, Dairen I, L-IPV, LC16M8, LC16MO, LIVP, Tian Tan, WR 65-16, Wyeth.

14. An anti-vaccinia composition, comprising one or more monoclonal antibodies, wherein at least two of said monoclonal antibodies are directed against L1R and A33R, in an amount effective for inhibiting vaccinia virus infection, and a pharmaceutically acceptable carrier.

17. A poxvirus monoclonal antibody composition comprising monoclonal antibodies against a homolog of a vaccinia antigen chosen from the group consisting of L1R and A33R, said poxvirus chosen from the group consisting of:

orthopoxvirus, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscimpoxvirus, and yatapoxvirus.